PD-L1在复发性非转移性骶脊索瘤中的表达评估——一项回顾性研究

IF 0.2 4区 医学 Q4 MEDICINE, GENERAL & INTERNAL
T. Zenginkinet, E. Okay, A. T. Toksoz Yildirim, A. Çelik, Y. Turhan, K. Ozkan, M. Akyurek
{"title":"PD-L1在复发性非转移性骶脊索瘤中的表达评估——一项回顾性研究","authors":"T. Zenginkinet, E. Okay, A. T. Toksoz Yildirim, A. Çelik, Y. Turhan, K. Ozkan, M. Akyurek","doi":"10.2298/sarh220524009z","DOIUrl":null,"url":null,"abstract":"Introduction/Objective. Chordomas are rare tumors of a notochordal origin. Wide surgical resection is recommended for treatment. However, it is associated with a high risk of morbidity and mortality. Additionally, these tumors are resistant to chemotherapy. Thus, targeted therapy is needed for the treatment of chordomas. Programmed death ligand 1 (PD-L1) is a promising target for cancer treatment. Here, we investigated PD-L1 expression in patients with chordoma in a single-center study. Methods. Formalin-fixed paraffin-embedded blocks were evaluated for immunohistochemical analysis to evaluate PD-L1 expression. Clinicopathological variables, such as sex, age, and follow-up data (recurrence and outcome), were retrospectively collected from the patients? medical records. Results. Ten patients diagnosed with sacral chordoma in a single institution between December 2015 and November 2021 were included in this study. The median patient age was 57 years and the median follow-up period was 40 months. The surgical margins were negative in all cases, without any preoperative medical treatment. Four of the ten patients showed PD-L1 positivity on immune cells. These patients showed local recurrence, without metastasis. In these cases, the median time to local recurrence was 15 months. All the patients with the disease were alive. Conclusion. This study demonstrated that PD-L1 positivity in immune cells can be used as a predictive marker for local recurrence at the time of surgical treatment. This can potentially be used to determine the necessity to administer immunotherapy.","PeriodicalId":22263,"journal":{"name":"Srpski arhiv za celokupno lekarstvo","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of PD-L1 expression in recurrent nonmetastatic sacral chordomas - a retrospective study\",\"authors\":\"T. Zenginkinet, E. Okay, A. T. Toksoz Yildirim, A. Çelik, Y. Turhan, K. Ozkan, M. Akyurek\",\"doi\":\"10.2298/sarh220524009z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction/Objective. Chordomas are rare tumors of a notochordal origin. Wide surgical resection is recommended for treatment. However, it is associated with a high risk of morbidity and mortality. Additionally, these tumors are resistant to chemotherapy. Thus, targeted therapy is needed for the treatment of chordomas. Programmed death ligand 1 (PD-L1) is a promising target for cancer treatment. Here, we investigated PD-L1 expression in patients with chordoma in a single-center study. Methods. Formalin-fixed paraffin-embedded blocks were evaluated for immunohistochemical analysis to evaluate PD-L1 expression. Clinicopathological variables, such as sex, age, and follow-up data (recurrence and outcome), were retrospectively collected from the patients? medical records. Results. Ten patients diagnosed with sacral chordoma in a single institution between December 2015 and November 2021 were included in this study. The median patient age was 57 years and the median follow-up period was 40 months. The surgical margins were negative in all cases, without any preoperative medical treatment. Four of the ten patients showed PD-L1 positivity on immune cells. These patients showed local recurrence, without metastasis. In these cases, the median time to local recurrence was 15 months. All the patients with the disease were alive. Conclusion. This study demonstrated that PD-L1 positivity in immune cells can be used as a predictive marker for local recurrence at the time of surgical treatment. This can potentially be used to determine the necessity to administer immunotherapy.\",\"PeriodicalId\":22263,\"journal\":{\"name\":\"Srpski arhiv za celokupno lekarstvo\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Srpski arhiv za celokupno lekarstvo\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2298/sarh220524009z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Srpski arhiv za celokupno lekarstvo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2298/sarh220524009z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

介绍/目标。脊索瘤是一种罕见的起源于脊索的肿瘤。建议广泛手术切除治疗。然而,它与高发病率和死亡率有关。此外,这些肿瘤对化疗有抗药性。因此,脊索瘤的治疗需要靶向治疗。程序性死亡配体1 (PD-L1)是一个很有前景的癌症治疗靶点。在这里,我们在一项单中心研究中研究了脊索瘤患者中PD-L1的表达。方法。用福尔马林固定石蜡包埋块进行免疫组织化学分析,以评估PD-L1的表达。回顾性收集患者的临床病理变量,如性别、年龄和随访数据(复发和结局)。医疗记录。结果。2015年12月至2021年11月在同一家机构诊断为骶脊索瘤的10例患者纳入本研究。患者中位年龄为57岁,中位随访时间为40个月。所有病例的手术切缘均为阴性,术前未进行任何治疗。10例患者中有4例免疫细胞PD-L1阳性。这些患者表现为局部复发,无转移。在这些病例中,局部复发的中位时间为15个月。所有的病人都还活着。结论。本研究表明免疫细胞中PD-L1阳性可作为手术治疗时局部复发的预测指标。这可以潜在地用于确定实施免疫治疗的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of PD-L1 expression in recurrent nonmetastatic sacral chordomas - a retrospective study
Introduction/Objective. Chordomas are rare tumors of a notochordal origin. Wide surgical resection is recommended for treatment. However, it is associated with a high risk of morbidity and mortality. Additionally, these tumors are resistant to chemotherapy. Thus, targeted therapy is needed for the treatment of chordomas. Programmed death ligand 1 (PD-L1) is a promising target for cancer treatment. Here, we investigated PD-L1 expression in patients with chordoma in a single-center study. Methods. Formalin-fixed paraffin-embedded blocks were evaluated for immunohistochemical analysis to evaluate PD-L1 expression. Clinicopathological variables, such as sex, age, and follow-up data (recurrence and outcome), were retrospectively collected from the patients? medical records. Results. Ten patients diagnosed with sacral chordoma in a single institution between December 2015 and November 2021 were included in this study. The median patient age was 57 years and the median follow-up period was 40 months. The surgical margins were negative in all cases, without any preoperative medical treatment. Four of the ten patients showed PD-L1 positivity on immune cells. These patients showed local recurrence, without metastasis. In these cases, the median time to local recurrence was 15 months. All the patients with the disease were alive. Conclusion. This study demonstrated that PD-L1 positivity in immune cells can be used as a predictive marker for local recurrence at the time of surgical treatment. This can potentially be used to determine the necessity to administer immunotherapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Srpski arhiv za celokupno lekarstvo
Srpski arhiv za celokupno lekarstvo MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
50.00%
发文量
104
审稿时长
4-8 weeks
期刊介绍: Srpski Arhiv Za Celokupno Lekarstvo (Serbian Archives of Medicine) is the Journal of the Serbian Medical Society, founded in 1872, which publishes articles by the members of the Serbian Medical Society, subscribers, as well as members of other associations of medical and related fields. The Journal publishes: original articles, communications, case reports, review articles, current topics, articles of history of medicine, articles for practitioners, articles related to the language of medicine, articles on medical ethics (clinical ethics, publication ethics, regulatory standards in medicine), congress and scientific meeting reports, professional news, book reviews, texts for "In memory of...", i.e. In memoriam and Promemoria columns, as well as comments and letters to the Editorial Board. All manuscripts under consideration in the Serbian Archives of Medicine may not be offered or be under consideration for publication elsewhere. Articles must not have been published elsewhere (in part or in full).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信